All In Biotech

Drug Trial Radar · NCT05797610

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 459 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

459

Actual

Start

Aug 8, 2023

Primary completion

May 25, 2028

Study completion Aug 31, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

Conditions

  • Primary IgA Nephropathy

Interventions

  • Sefaxersen (RO7434656)Drug

    Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified in the protocol.

  • PlaceboDrug

    Matching placebo will be administered as SC injection per schedule as specified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37Time frame: Baseline, Week 37

Locations

162 sites in 21 countries. Site status is shown where the registry gives one.

  • UAB Nephrology Research Clinic

    Birmingham, Alabama

  • Kidney Disease Medical Group Inc-1505 Wilson Ter

    Glendale, California

  • Academic Medical Research Institute - Los Angeles

    Los Angeles, California

  • UCLA University of California Los Angeles

    Los Angeles, California

  • North America Research Institute-San Dimas

    San Dimas, California

  • Central Florida Kidney Specialists

    Orlando, Florida

  • L&C Professional Medical Research Institute

    West Miami, Florida

  • Cowry Medical Group LLC

    Acworth, Georgia

  • Care Institute Idaho Kidney Institute

    Idaho Falls, Idaho

  • Nephrology Associates of Northern Illinois

    Hinsdale, Illinois

  • Massachussets General Hospital

    Boston, Massachusetts

  • Sierra Nevada Nephrology Consultants

    Reno, Nevada

  • North Carolina Nephrology, PA

    Raleigh, North Carolina

  • Texas Kidney Institute - Dallas

    Dallas, Texas

  • Pioneer Research Solutions

    Houston, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • R & H Clinical Research

    Katy, Texas

  • Revival Research Institute - McKinney

    McKinney, Texas

  • Nephrology Associates of Northern Virginia Inc

    Fairfax, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Ciudad Autonoma Buenos Aires, Argentina

  • Consultorios Médicos Dr. Doreski

    Ciudad Autonoma Buenos Aires, Argentina

  • Sanatorio Mayo Privado

    Córdoba, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Sunshine Hospital

    St Albans, Victoria, Australia

  • Instituto D?Or Pesquisa e Ensino - Hospital Gloria D?Or

    Rio de Janeiro, Brazil

  • Santa Casa de Misericordia de Belo Horizonte - PPDS

    Belo Horizonte, Minas Gerais, Brazil

  • Freire Pesquisa Clinica

    Belo Horizonte, Minas Gerais, Brazil

  • Hospital de Clinicas de Porto Alegre HCPA PPDS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Hospital Do Rim E Hipertensao Fundacao Oswaldo Ramos

    São Paulo, São Paulo, Brazil

  • Centre Hospitalier Universitaire de Quebec

    Québec, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.